Proteomics company Alamar Biosciences closed $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days. This new capital brings Alamar's total funding to date to nearly $250 million. The financing round was led by Sands Capital and included participation from new financial […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!